Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Raul Nogueira

Vascular Neurology Pittsburgh, PA Medical Doctor

NPI 1912975921 CMS profile 358860

200 Lothrop St, Pittsburgh, PA 15213

Open in the dashboard

General payments

$927,961

257 records reported · program years 2019–2025

Research payments

$3,959

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$900,473

7 holdings reported · through program year 2025

Research they led as principal investigator

$5,618,545 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Raul Nogueira of Pittsburgh, PA is reported in the CMS Open Payments database as having received $927,961 across 257 general payments and $3,959 in research payments paid to them. Separately, studies naming them as principal investigator received $5,618,545 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $900,473 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Vascular Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $50,666 30
2024 General $22,890 16
2023 General $38,302 50
2022 General $51,510 53
2021 General $74,122 36
2021 Research $3,800 1
2020 General $87,257 10
2020 Research $159 1
2019 General $603,214 62
2025 Ownership $237,951 2
2024 Ownership $85,113 1
2023 Ownership $64,976 1
2022 Ownership $193,908 1
2021 Ownership $318,525 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raul Nogueira
  • Vascular Neurology median
  • Middle half of Vascular Neurology
  • National median

In program year 2025, general payments to Raul Nogueira were reported at $50,666. Among 416 Vascular Neurology profiles paid that year, the median was $360 and the middle half received between $91 and $1,472.

Show as a table
Year Raul Nogueira Vascular Neurology median Middle half National median
2019 $603,214 $263 $102–$1,640 $163
2020 $87,257 $153 $45–$1,000 $114
2021 $74,122 $261 $100–$1,355 $132
2022 $51,510 $242 $87–$1,273 $149
2023 $38,302 $322 $97–$1,266 $160
2024 $22,890 $247 $70–$1,053 $164
2025 $50,666 $360 $91–$1,472 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Corindus Inc. $477,799 5 payments
  2. Stryker Corporation $210,793 99 payments
  3. Medical Device Business Services, Inc. $126,576 82 payments
  4. NeuroVasc Technologies, Inc. $31,664 3 payments
  5. Medtronic, Inc. $16,563 16 payments
  6. phenox Inc. $16,502 3 payments
  7. Route 92 Medical, Inc. $12,544 6 payments
  8. Perfuze Limited $8,401 2 payments
  9. Imperative Care, INc $6,252 4 payments
  10. Biogen, Inc. $4,420 12 payments
  11. Other $16,446 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Current or prospective ownership or investment interest $477,000 1 payment
  2. Consulting Fee $338,067 62 payments
  3. Travel and Lodging $85,025 85 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21,550 11 payments
  5. Food and Beverage $6,318 98 payments
Products named General payments · program years 2019–2025
  1. TREVO Microcatheterstentriever $113,738 14 payments
  2. ATLAS $40,896 6 payments
  3. EMBOGUARD $34,437 15 payments
  4. TARGET $29,571 4 payments
  5. NEUROFORM EZ $29,409 4 payments
  6. TREVO Microcatheterstentriever $28,366 13 payments
  7. EMBOTRAP II Revascularization Device $24,805 14 payments
  8. AXS CATALYST 7 $18,584 13 payments
  9. FLOWGATE2 $18,584 13 payments
  10. pRESET $16,200 1 payment
  11. Other $242,260 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Biogen, Inc. $3,959 2 payments

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$46,142

Medicare's payments for the services billed

Medicare patients

56

Average age 76

Services billed

220

27 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Ischemic heart disease 50%
Atrial fibrillation 41%
Heart failure 36%
Chronic kidney disease 36%
Depression 36%
Diabetes 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

259 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Neurology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record